Page 277 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 277
P0899 PRECLINICAL PROFILE OF THE PAN-GENOTYPIC HCV ePOSTERS
P0900 NS3/4A PROTEASE INHIBITOR GS-9857
P0901 James G. Taylor*, Todd Appleby, Ona Barauskas, Xiaowu Chen,
Hadas Dvory-Sobol, Ruoyu Gong, Johnny Lee, Elham Nejati,
P0902 Brian Schultz,Yujin Wang, Chris Yang, Mei Yu, Sheila Zipfel, Katie Chan,
P0903 The United States
CONSIDERATION OF VIRAL RESISTANCE FOR
OPTIMIZATION OF DIRECT ANTIVIRAL THERAPY OF
CHRONIC HEPATITIS C
Julia Dietz*, Caterina Berkowski, Dany Perner, Simone Susser,
Stefan Zeuzem, Christoph Sarrazin, Germany
THE PAN-GENOTYPIC NS3/4A PROTEASE INHIBITOR GS-
9857 DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN
PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4 IN
A 3-DAY MONOTHERAPY STUDY
Maribel Rodriguez-Torres*, Steven Glass, John Hill, Bradley Freilich,
David Hassman, Adrian Di Bisceglie, James G. Taylor, Brian Kirby,
Jenny C. Yang, Luisa M. Stamm, Diana M. Brainard, Suzanne Kim,
David Krefetz, William Smith, Thomas Marbury, Eric Lawitz, Puerto Rico
EXPOSURE-RESPONSE ANALYSES FOR EFFICACY (SVR12)
FOR THE DIRECT ACTING ANTIVIRAL REGIMEN OF ABT-
450/R, OMBITASVIR WITH DASABUVIR ± RIBAVIRIN IN
SUBJECTS WITH HCV GENOTYPE 1 INFECTION
Amit Khatri*, Sven Mensing, Thomas Podsadecki, Walid Awni,
Rajeev Menon, Sandeep Dutta, The United States
SLOW HCV KINETICS FOLLOWING SOFOSBUVIR +
RIBAVIRIN ADMINISTRATION IN REAL-LIFE SETTING
OF LIVER TRANSPLANT RECIPIENTS WITH SEVERE
RECURRENT HEPATITIS C
Valeria Cento, Maria Francesca Donato, Ilaria Lenci, Maria Rendina,
Martina Milana, Velia Chiara Di Maio, Sara Monico, Marianna Aragri,
Roberta Alfieri, Amal Abedrabbo, Daniele Sforza, Matteo Manuelli,
Laura Mameli, Maria Chiara Sorbo, Roberto Canu, Maria Laura Ponti,
Claudia Chialà, Federica Malinverno, Simona Marenco,
Luciano Milanesi, Antonino Picciotto, Giorgio Rossi, Alfredo Di Leo,
Giuseppe Tisone, Fausto Zamboni, Roberto Ganga, Massimo Colombo,
Carlo Federico Perno, Mario Angelico, Francesca Ceccherini-Silberstein*,
Italy
Vienna, Austria • April 22–26, 2015 277
P0900 NS3/4A PROTEASE INHIBITOR GS-9857
P0901 James G. Taylor*, Todd Appleby, Ona Barauskas, Xiaowu Chen,
Hadas Dvory-Sobol, Ruoyu Gong, Johnny Lee, Elham Nejati,
P0902 Brian Schultz,Yujin Wang, Chris Yang, Mei Yu, Sheila Zipfel, Katie Chan,
P0903 The United States
CONSIDERATION OF VIRAL RESISTANCE FOR
OPTIMIZATION OF DIRECT ANTIVIRAL THERAPY OF
CHRONIC HEPATITIS C
Julia Dietz*, Caterina Berkowski, Dany Perner, Simone Susser,
Stefan Zeuzem, Christoph Sarrazin, Germany
THE PAN-GENOTYPIC NS3/4A PROTEASE INHIBITOR GS-
9857 DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN
PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4 IN
A 3-DAY MONOTHERAPY STUDY
Maribel Rodriguez-Torres*, Steven Glass, John Hill, Bradley Freilich,
David Hassman, Adrian Di Bisceglie, James G. Taylor, Brian Kirby,
Jenny C. Yang, Luisa M. Stamm, Diana M. Brainard, Suzanne Kim,
David Krefetz, William Smith, Thomas Marbury, Eric Lawitz, Puerto Rico
EXPOSURE-RESPONSE ANALYSES FOR EFFICACY (SVR12)
FOR THE DIRECT ACTING ANTIVIRAL REGIMEN OF ABT-
450/R, OMBITASVIR WITH DASABUVIR ± RIBAVIRIN IN
SUBJECTS WITH HCV GENOTYPE 1 INFECTION
Amit Khatri*, Sven Mensing, Thomas Podsadecki, Walid Awni,
Rajeev Menon, Sandeep Dutta, The United States
SLOW HCV KINETICS FOLLOWING SOFOSBUVIR +
RIBAVIRIN ADMINISTRATION IN REAL-LIFE SETTING
OF LIVER TRANSPLANT RECIPIENTS WITH SEVERE
RECURRENT HEPATITIS C
Valeria Cento, Maria Francesca Donato, Ilaria Lenci, Maria Rendina,
Martina Milana, Velia Chiara Di Maio, Sara Monico, Marianna Aragri,
Roberta Alfieri, Amal Abedrabbo, Daniele Sforza, Matteo Manuelli,
Laura Mameli, Maria Chiara Sorbo, Roberto Canu, Maria Laura Ponti,
Claudia Chialà, Federica Malinverno, Simona Marenco,
Luciano Milanesi, Antonino Picciotto, Giorgio Rossi, Alfredo Di Leo,
Giuseppe Tisone, Fausto Zamboni, Roberto Ganga, Massimo Colombo,
Carlo Federico Perno, Mario Angelico, Francesca Ceccherini-Silberstein*,
Italy
Vienna, Austria • April 22–26, 2015 277
